201 related articles for article (PubMed ID: 16623819)
1. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Levi ME; Mandava N; Chan LK; Weinberg A; Olson JL
Transpl Infect Dis; 2006 Mar; 8(1):38-43. PubMed ID: 16623819
[TBL] [Abstract][Full Text] [Related]
2. Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.
Dunn JH; Weinberg A; Chan LK; Mandava N; Levi ME; Olson JL
JAMA Ophthalmol; 2013 Jul; 131(7):958-60. PubMed ID: 23846207
[No Abstract] [Full Text] [Related]
3. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
[TBL] [Abstract][Full Text] [Related]
4. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
John GT; Manivannan J; Chandy S; Peter S; Fleming DH; Chandy SJ; Balakrishnan N; Krishnamurthy K; Kirubakaran MG; Jacob CK
Transplant Proc; 2005 Dec; 37(10):4303-5. PubMed ID: 16387103
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K; Groll AH; Kuehn J; Vormoor J
Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
[TBL] [Abstract][Full Text] [Related]
7. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
[TBL] [Abstract][Full Text] [Related]
9. Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Goldsmith PM; Husain MM; Carmichael A; Zhang H; Middleton SJ
Transplantation; 2012 Apr; 93(7):e30-2. PubMed ID: 22450598
[No Abstract] [Full Text] [Related]
10. Intraocular therapy for cytomegalovirus retinitis.
Palestine AG
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):25-8. PubMed ID: 11363527
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide for cytomegalovirus: bench to bedside.
Chacko B; John GT
Transpl Infect Dis; 2012 Apr; 14(2):111-20. PubMed ID: 22093814
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide use in renal transplantation.
Leca N
Curr Opin Organ Transplant; 2009 Aug; 14(4):370-4. PubMed ID: 19512928
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile and immunological status of cytomegalovirus retinitis in organ transplant recipients.
Wagle AM; Biswas J; Gopal L; Madhavan HN
Indian J Ophthalmol; 2002 Jun; 50(2):115-21. PubMed ID: 12194567
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Waldman WJ; Knight DA; Lurain NS; Miller DM; Sedmak DD; Williams JW; Chong AS
Transplantation; 1999 Sep; 68(6):814-25. PubMed ID: 10515382
[TBL] [Abstract][Full Text] [Related]
15. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
Fu L; Santhanakrishnan K; Al-Aloul M; Jones NP; Steeples LR
Ocul Immunol Inflamm; 2020 Oct; 28(7):1152-1158. PubMed ID: 31621449
[No Abstract] [Full Text] [Related]
16. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.
Waldman WJ; Knight DA; Blinder L; Shen J; Lurain NS; Miller DM; Sedmak DD; Williams JW; Chong AS
Intervirology; 1999; 42(5-6):412-8. PubMed ID: 10702725
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and outcomes of cytomegalovirus retinitis after transplantation.
Eid AJ; Bakri SJ; Kijpittayarit S; Razonable RR
Transpl Infect Dis; 2008 Feb; 10(1):13-8. PubMed ID: 17511815
[TBL] [Abstract][Full Text] [Related]
19. [Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
Gómez Valbuena I; Alioto D; Serrano Garrote O; Ferrari Piquero JM
Farm Hosp; 2016 Jan; 40(1):52-4. PubMed ID: 26882834
[TBL] [Abstract][Full Text] [Related]
20. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
